Selamectin

Names

[ CAS No. ]:
220119-17-5

[ Name ]:
Selamectin

[Synonym ]:
(2aE,4E,5'S,6S,6'S,7S,8E,11R,13R,15S,17aR,20Z,20aR,20bS)-6'-cyclohexyl-20b-hydroxy-20-(hydroxyimino)-5',6,8,19-tetramethyl-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranoside
(1'R,2R,4'S,5S,6S,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'Z,24'S)-6-Cyclohexyl-24'-hydroxy-21'-(hydroxyimino)-5,11',13',22'-tetramethyl-2'-oxo-3,4,5,6-tetrahydrospiro[pyran-2,6'-[3,7,19]trioxatetracyclo[ ;15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-12'-yl 2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranoside
hypnocarpic acid
(1'R,2R,4'S,5S,6S,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'Z,24'S)-6-Cyclohexyl-24'-hydroxy-21'-(hydroxyimino)-5,11',13',22'-tetramethyl-2'-oxo-3,4,5,6-tetrahydrospiro[pyran-2,6'-[3,7,19]trioxatetracyclo[15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-12'-yl-2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranoside
(1'R,2R,4'S,5S,6S,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'Z,24'S)-6-Cyclohexyl-24'-hydroxy-21'-(hydroxyimino)-5,11',13',22'-tetramethyl-2'-oxo-3,4,5,6-tetrahydrospiro[pyran-2,6'-[3,7,19]trioxatetracyclo[15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-12'-yl 2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranoside
Stronghold
Selamectin
Revolution

Biological Activity

[Description]:

Selamectin is an anthelminthic which can be used on dogs and cats.

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Infection

[In Vivo]

Three monthly treatments with Selamectin/sarolaner provide high and consistent efficacy against I. ricinus for the entire duration of the study period. The percentage efficacy against I. ricinus is numerically higher in the Selemectin/sarolaner treating group than in the fluralaner-treating group on Days 56, 84 and 91[1]. All dogs are tested negative by both tests after receiving topical treatment with Selamectin monthly for 36 months[2].

[Animal admin]

The cats are weighed on Days-2, 29 and 58 to calculate the dosing. Cats in group 1 (control group) remain untreated. On Day 0, the cats in group 3 are treated with fluralaner at the minimum recommending label dose of 40.0 mg per kg body weight. On Days 0, 30 and 60, the cats in group 2 are treated with the new spot-on formulation at the minimum recommending label dose of 1.0 mg/kg sarolaner and 6.0 mg/kg Selamectin. The cats are observed at different time points after treatment for possible adverse reactions to treatment. On Day 0, administration site observations are performed on all cats 30 min (±5 min), 3 h (±15 min) and 24 h (±1 h) and again on Days 3 and 5 after treatment[1].

[References]

[1]. Thomas Geurden, et al. Comparative efficacy of a new spot-on combination product containing selamectin and sarolaner (Stronghold®Plus) versus fluralaner (Bravecto®) against induced infestations with Ixodes ricinus ticks on cats. Published online 2017 Jun 29.

[2]. Maria de Fátima Chicarino Varajao Moraes-da-Silva, et al. Selamectin for the prevention of canine Dirofilaria immitis infection: field efficacy in client-owned dogs in a high risk area. Published online 2016 Jul 22.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
917.0±65.0 °C at 760 mmHg

[ Molecular Formula ]:
C₄₃H₆₃NO₁₁

[ Molecular Weight ]:
769.960

[ Flash Point ]:
508.4±34.3 °C

[ Exact Mass ]:
769.440125

[ PSA ]:
154.73000

[ LogP ]:
6.83

[ Vapour Pressure ]:
0.0±0.6 mmHg at 25°C

[ Index of Refraction ]:
1.618

[ Storage condition ]:
2-8°C

Safety Information

[ RIDADR ]:
NONH for all modes of transport

Articles

Determination of avermectins: a QuEChERS approach to the analysis of food samples.

Food Chem. 181 , 57-63, (2015)

We present a simple method for extracting avermectines from meat, based on a QuEChERS approach followed by liquid chromatography (LC) coupled to triple quadrupole (QqQ) tandem mass spectrometry (MS/MS...

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer.

EMBO Mol. Med. 6(10) , 1263-78, (2014)

Constitutive activation of canonical WNT-TCF signaling is implicated in multiple diseases, including intestine and lung cancers, but there are no WNT-TCF antagonists in clinical use. We have performed...